CD19-targeted CAR T Cells for Relapsed and Refractory (R/R) Large B-cell Lymphoma

PHASE2Active, not recruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

August 17, 2023

Primary Completion Date

October 30, 2024

Study Completion Date

March 31, 2025

Conditions

Lymphoma, Non-HodgkinDiffuse Large B Cell Lymphoma

Interventions

BIOLOGICAL

CD19-targeted Chimeric Antigen Receptor(CAR) T Cells

Relma-cel be administered at one dose level:1×10\^8 CAR+T cells

Trial Locations (1)

Tianjin Cancer Hospital, Tianjin

All Listed Sponsors

lead

Shanghai Ming Ju Biotechnology Co., Ltd.

INDUSTRY

NCT06149169 - CD19-targeted CAR T Cells for Relapsed and Refractory (R/R) Large B-cell Lymphoma | Biotech Hunter | Biotech Hunter